Replimune (REPL) Tax Rate (2023 - 2026)

Replimune (REPL) posted Tax Rate of 0.39% for Q1 2026, down 6.57% sequentially from 0.42% in Q4 2025, and up 29.0% YoY from 0.3% in Q1 2025.

Analysis

Replimune (REPL) Tax Rate (2023 - 2026) Analysis & Trends

Replimune has reported Tax Rate for 4 years, with the latest figure at 0.39% in Q1 2026.

Quarterly Tax Rate rose 29.0% year-over-year to 0.39% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.02% (up 23.0% YoY) and the FY2026 annual result came in at 0.19%, up 39.0% from the prior year.
Tax Rate slipped to 0.39% in Q1 2026 per REPL's latest filing, from 0.42% in the prior quarter.
Over five years, Tax Rate peaked at 0.42% in Q4 2025 and troughed at 0.93% in Q4 2023.
A 4-year average of 0.16% and a median of 0.1% in 2025 frame the typical range for Tax Rate.
The widest YoY moves for Tax Rate: up 130 bps in 2025, down 2 bps in 2025.
Over 4 years, Tax Rate stood at 0.93% in 2023, then increased by 6 bps to 0.87% in 2024, then jumped by 148 bps to 0.42% in 2025, then declined by 7 bps to 0.39% in 2026.
According to Business Quant data, Tax Rate over the past three periods registered 0.39%, 0.42%, and 0.1% for Q1 2026, Q4 2025, and Q1 2025 respectively.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Tax Rate (Qtr)
1	Vertex Pharmaceuticals	139.76 Bn	131.91 Bn	2.84 Bn	20.98%
2	Regeneron Pharmaceuticals	85.72 Bn	77.72 Bn	3.93 Bn	15.11%
3	Argenx Se	63.56 Bn	58.38 Bn	1.37 Bn	-10.89%
4	Moderna	57.87 Bn	52.73 Bn	52.00 Mn	-1.96%
5	Revolution Medicines	44.06 Bn	44.06 Bn	-	-
6	BeOne Medicines	40.08 Bn	34.98 Bn	1.53 Bn	24.15%
7	Alnylam Pharmaceuticals	35.50 Bn	32.20 Bn	992.69 Mn	7.49%
8	Royalty Pharma	28.54 Bn	27.70 Bn	-	-
9	Insmed	27.49 Bn	26.33 Bn	358.27 Mn	-16.71%
10	Replimune	1.46 Bn	1.46 Bn	-	-

Historic Data

Download Data